Fagron NV (FAGR)
Euronext Brussels · Belgium · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 23.40 |
|---|---|
| 52-week range | 20.00 – 25.30 |
| Return, 1 month / 3 months | +5.4% / −1.3% |
| Return, 1 year / 3 years | +13.0% / +54.4% |
| Trend | Uptrend |
| RSI (14) | 60 |
| Volatility (1 year) | 21.2% |
| Worst drawdown (1 year) | -16.8% |
| Average daily value traded | 2.27M EUR |
| Dividend yield | 1.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Fagron is a pharmaceutical compounding company based in Belgium. It supplies pharmacies, hospitals and clinics with the ingredients, excipients and equipment needed to prepare custom-made medicines, along with ready-to-use compounding products and related services. Its customers include community pharmacists, hospital pharmacies and other healthcare providers, and it operates across Europe, the Americas and other regions through local subsidiaries and production sites.
On this site Fagron NV appears as a stock on the Euronext Brussels (Belgium), code FAGR, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Fagron NV (FAGR) trades on the Euronext Brussels in Belgium. It last closed at EUR 23.40 on 22 October 2026.
Its price-based Market X-Ray is 66 out of 100 (a fair price profile), ranking 29 of 111 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 13.0% and over the last three months it fell 1.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Brussels
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 68 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 2.7% | ||
| From 52-week high | -7.3% | ||
| Momentum | 61 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -1.3% | ||
| 6-month return | -0.5% | ||
| 12-month return, skipping the last month | 7.2% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 21.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.8% | ||
| Liquidity | 80 · Strong | Trades actively. | |
| Average daily value traded | 2.27M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 40 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.7% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.9% |
|---|---|
| 1 month | +5.4% |
| 3 months | −1.3% |
| 6 months | −0.5% |
| 1 year | +13.0% |
| 3 years | +54.4% |
| 5 years | +63.1% |
Signals
| 50-day / 200-day average | 22.33 / 22.79 |
|---|---|
| Golden / death cross (60 days) | Death, 23 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.52 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 May 2026 | EUR 0.4000 |
| 19 May 2025 | EUR 0.3500 |
| 21 May 2024 | EUR 0.3000 |
| 15 May 2023 | EUR 0.2500 |
| 16 May 2022 | EUR 0.2000 |
| 17 May 2021 | EUR 0.1800 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Brussels; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.